e body by the lining of the inner mouth using the Company's proprietary RapidMist™ device. The Company's flagship product, buccal insulin (Generex Oral-lyn™), which has been approved in India, Lebanon, Algeria, and Ecuador for the treatment of subjects with Type-1 and Type-2 diabetes, is in Phase III clinical trials at several sites around the world. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases. For more information, visit the Generex website at
www.generex.com or the Antigen Express website at
www.antigenexpress.com. Information contained in, or accessible through, the websites of Generex or Antigen Express is not incorporated herein and is not a part of the proxy soliciting material.
Safe Harbor Statement
This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects," or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of whi
'/>"/>
SOURCE Generex Biotechnology Corporation Copyright©2010 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 Related biology technology :1.
Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation2.
Metamark Genetics, Inc. Announces New Chief Scientific Officer3.
Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences4.
Dendreon Announces Change in Board of Directors5.
Executive Mindshare Announces New Social Media Platform for Vertical Business Networks6.
DSM Biomedical Announces Continued Partnership with Spinelab7.
Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC8.
Stemedica Announces Completion of Clinical Stem Cell Master Bank9.
DATATRAK International, Inc. Announces Initial Equity Research Coverage by Zacks Investment Research10.
RRD Announces Move to New Corporate Headquarters11.
Huifeng Bio-Pharmaceutical Technology, Inc. Announces the Acquisition of Shangqiu Kexin Rutin Processing Ltd.